- Home
- ALDX vs CLLS Comparison
ALDX vs CLLS Comparison
Compare ALDX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- CLLS
- Stock Information
- Founded
- ALDX 2004
- CLLS 1999
- Country
- ALDX United States
- CLLS France
- Employees
- ALDX N/A
- CLLS N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- CLLS Health Care
- Exchange
- ALDX Nasdaq
- CLLS Nasdaq
- Market Cap
- ALDX 313.4M
- CLLS 299.0M
- IPO Year
- ALDX 2014
- CLLS 2007
- Fundamental
- Price
- ALDX $5.26
- CLLS $3.98
- Analyst Decision
- ALDX Strong Buy
- CLLS Buy
- Analyst Count
- ALDX 2
- CLLS 1
- Target Price
- ALDX $9.50
- CLLS $8.00
- AVG Volume (30 Days)
- ALDX 647.5K
- CLLS 224.4K
- Earning Date
- ALDX 11-06-2025
- CLLS 11-03-2025
- Dividend Yield
- ALDX N/A
- CLLS N/A
- EPS Growth
- ALDX N/A
- CLLS N/A
- EPS
- ALDX N/A
- CLLS N/A
- Revenue
- ALDX N/A
- CLLS $63,438,000.00
- Revenue This Year
- ALDX N/A
- CLLS N/A
- Revenue Next Year
- ALDX $36.23
- CLLS $66.76
- P/E Ratio
- ALDX N/A
- CLLS N/A
- Revenue Growth
- ALDX N/A
- CLLS 223.09
- 52 Week Low
- ALDX $1.14
- CLLS $1.10
- 52 Week High
- ALDX $7.20
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- ALDX 48.59
- CLLS 56.39
- Support Level
- ALDX $5.13
- CLLS $3.93
- Resistance Level
- ALDX $5.79
- CLLS $5.48
- Average True Range (ATR)
- ALDX 0.28
- CLLS 0.39
- MACD
- ALDX -0.00
- CLLS 0.03
- Stochastic Oscillator
- ALDX 29.10
- CLLS 46.22
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.